Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.
The exact annual incidence of GBM is not available for the country; however, 2013 data reports 982 new cases of glioblastoma, constituting 62% of all neuroepithelial tumor cases. The median age of diagnosis was reported to be 65 years. The Australian health system is well organized and jointly run by federal, state & territory, and local government.
Medicare and the public health system provide full coverage or cover most of the expenses of healthcare services. Australian government to boost the Brain Cancer Mission, which aims to increase the overall survival rate of brain cancer and improve the quality of life of brain cancer patients. The Australian government has partnered with researchers, philanthropists, clinicians, patients, and their families, to achieve the goal of the mission.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into Australia glioblastoma multiforme treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account